ERBB2 and cancer: Some studies have suggested discordance between the primary and nodal cancer happens often—more than 30% for ER, 40% for PR and 24% for HER2 [108]—and others say it is not often enough to warrant evaluating biomarkers in all positive nodes [109,110], and yet others suggest it is somewhere in between [111,112].